Free Trial

Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 5.80 +0.10 (+1.75%)
As of 04/17/2025 11:50 AM Eastern

AGY vs. INDV, AMYT, APH, ANCR, VLG, DNL, EAH, STX, PXS, and CHLL

Should you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), Shield Therapeutics (STX), Provexis (PXS), and Chill Brands Group (CHLL). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Allergy Therapeutics vs.

Allergy Therapeutics (LON:AGY) and Indivior (LON:INDV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.

Allergy Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.

86.0% of Indivior shares are held by institutional investors. 93.0% of Allergy Therapeutics shares are held by insiders. Comparatively, 3.4% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Indivior has a net margin of -0.17% compared to Allergy Therapeutics' net margin of -72.86%. Indivior's return on equity of -0.77% beat Allergy Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-72.86% -266.59% -34.76%
Indivior -0.17%-0.77%2.37%

Indivior received 198 more outperform votes than Allergy Therapeutics when rated by MarketBeat users. Likewise, 80.43% of users gave Indivior an outperform vote while only 77.97% of users gave Allergy Therapeutics an outperform vote.

CompanyUnderperformOutperform
Allergy TherapeuticsOutperform Votes
361
77.97%
Underperform Votes
102
22.03%
IndiviorOutperform Votes
559
80.43%
Underperform Votes
136
19.57%

Indivior has higher revenue and earnings than Allergy Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£72.18M3.95-£52.59M-£1.04-5.59
Indivior£1.40B0.77-£2.36M-£1.21-570.87

In the previous week, Allergy Therapeutics and Allergy Therapeutics both had 1 articles in the media. Indivior's average media sentiment score of 0.59 beat Allergy Therapeutics' score of 0.37 indicating that Indivior is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allergy Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Indivior
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Indivior has a consensus target price of GBX 1,650, indicating a potential upside of 139.65%. Given Indivior's stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than Allergy Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allergy Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Indivior
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Indivior beats Allergy Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

MetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£285.07M£2.13B£5.31B£2.51B
Dividend Yield8.33%2.92%5.45%4.79%
P/E Ratio-5.594.3321.94130.39
Price / Sales3.95478.32380.95234,760.20
Price / Cash3.6610.2538.2628.28
Price / Book58.776.146.454.42
Net Income-£52.59M£20.70B£3.22B£5.89B
1 Month Performance-12.12%-3.01%-9.76%-1.36%
1 Year Performance118.87%93.89%11.49%41.35%

Allergy Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 5.80
+1.8%
N/A+103.5%£285.07M£72.18M-5.59612
INDV
Indivior
1.9809 of 5 stars
GBX 682
-1.9%
GBX 1,650
+141.9%
-54.8%£1.07B£1.40B-565.481,000Gap Down
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down
APH
Alliance Pharma
2.0835 of 5 stars
GBX 64.20
flat
GBX 6,250
+9,635.2%
+74.7%£347.61M£183.50M-10.3591,000
ANCR
Animalcare Group
N/AGBX 225
+2.3%
N/A+5.7%£154.26M£84.90M4.19220News Coverage
VLG
Venture Life Group
N/AGBX 40.45
-0.1%
N/A+5.3%£51.54M£51.77M68.64165News Coverage
DNL
Diurnal Group
N/AN/AN/AN/A£46.33M£4.68M-3.2133
EAH
ECO Animal Health Group
N/AGBX 52
-2.8%
N/A-43.2%£35.24M£89.44M33.61234
STX
Shield Therapeutics
N/AGBX 2.68
-4.3%
N/A+62.1%£26.45M£20.92M-0.6940,000Gap Down
PXS
Provexis
N/AGBX 0.52
-6.4%
N/A-17.6%£12.09M£846,984.38-19.524Gap Up
CHLL
Chill Brands Group
N/AN/AN/AN/A£10.89M£624,187.00-215.007

Related Companies and Tools


This page (LON:AGY) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners